4D Molecular Therapeutics financials
$14.49−0.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $85.2M | $37.0K | $20.7M | $3.1M | $18.0M | $13.6M |
| Gross profit | $85.2M | $37.0K | $20.7M | $3.1M | $18.0M | $13.6M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$159.5M | -$187.8M | -$112.9M | -$110.0M | -$71.3M | -$56.7M |
| Net income | -$140.1M | -$160.9M | -$100.8M | -$107.5M | -$71.3M | -$56.7M |
| Net margin | −164.4% | −434778.4% | −486.6% | −3435.4% | −395.4% | −416.5% |
| Diluted EPS | $-2.42 | $-2.98 | $-2.58 | $-3.32 | $-2.57 | $-8.82 |
| EBITDA | -$154.9M | -$183.2M | -$108.7M | -$106.1M | -$69.8M | -$55.2M |
| Operating cash flow | -$109.1M | -$134.6M | -$75.8M | -$86.7M | -$69.1M | -$50.9M |
| Free cash flow | -$109.6M | -$138.4M | -$78.6M | -$98.2M | -$78.2M | -$51.9M |
| Diluted shares | 57.9M | 53.9M | 39.1M | 32.4M | 27.7M | 6.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $60.2M | $149.3M | $249.1M | $52.4M | $153.0M | $276.7M |
| Short-term investments | $342.4M | $275.5M | $39.1M | $161.2M | $94.8M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $566.7M | $560.4M | $339.9M | $261.8M | $353.5M | $288.3M |
| Total liabilities | $61.0M | $49.8M | $32.1M | $30.5M | $34.4M | $31.9M |
| Shareholders' equity | $505.7M | $510.6M | $307.8M | $231.3M | $319.1M | $256.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology